Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Phenytoin | The metabolism of Ebastine can be increased when combined with Phenytoin. |
| Fosphenytoin | The metabolism of Ebastine can be increased when combined with Fosphenytoin. |
| Benzylpenicilloyl polylysine | Ebastine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Ebastine. |
| Amphetamine | Amphetamine may decrease the sedative activities of Ebastine. |
| Phentermine | Phentermine may decrease the sedative activities of Ebastine. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Ebastine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Ebastine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Ebastine. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Ebastine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Ebastine. |
| MMDA | MMDA may decrease the sedative activities of Ebastine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Ebastine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ebastine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ebastine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Ebastine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Ebastine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Ebastine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Ebastine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Ebastine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Ebastine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Ebastine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Ebastine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Ebastine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Ebastine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ebastine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Ebastine. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Goserelin. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Moxifloxacin. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Sulfisoxazole. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Sulpiride. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Droperidol. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ebastine. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Fluorouracil. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Perflutren. |
| Atropine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Atropine. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Adenosine. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Pentamidine. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Gadobenic acid. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Nalidixic acid. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Cinoxacin. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Levosimendan. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Mesoridazine. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Desloratadine. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Lomefloxacin. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Dimenhydrinate. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Papaverine. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Gemifloxacin. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Ofloxacin. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Flecainide. |
| Probucol | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Probucol. |
| Aceprometazine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Aceprometazine. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Terlipressin. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Lofexidine. |
| Azimilide | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Azimilide. |
| Pracinostat | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Pracinostat. |
| Technetium Tc-99m ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Technetium Tc-99m ciprofloxacin. |
| Garenoxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Garenoxacin. |
| Tedisamil | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Tedisamil. |
| Tucidinostat | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Tucidinostat. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Telavancin. |
| Nemonoxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Nemonoxacin. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Antazoline. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Butriptyline. |
| Melperone | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Melperone. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Amifampridine. |
| Mocetinostat | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Mocetinostat. |
| Entinostat | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Entinostat. |
| CUDC-101 | The risk or severity of QTc prolongation can be increased when Ebastine is combined with CUDC-101. |
| Simendan | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Simendan. |
| Ricolinostat | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Ricolinostat. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Mizolastine. |
| Abexinostat | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Abexinostat. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Oxatomide. |
| Sitafloxacin | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Sitafloxacin. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Sultopride. |
| Nizofenone | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Nizofenone. |
| Bunaftine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Bunaftine. |
| Lorcainide | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Lorcainide. |
| Dexchlorpheniramine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Dexchlorpheniramine. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Carbinoxamine. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Leuprolide. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Nimodipine. |
| Promazine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Promazine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Cinnarizine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Chloroquine. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Dolasetron. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Granisetron. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Ondansetron. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Chlorpheniramine. |
| Propafenone | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Propafenone. |
| Quetiapine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Quetiapine. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Prenylamine. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Fluspirilene. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Bedaquiline. |
| Fendiline | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Fendiline. |
| Eperisone | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Eperisone. |
| Dexchlorpheniramine maleate | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Dexchlorpheniramine maleate. |
| Otilonium | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Otilonium. |
| Penfluridol | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Penfluridol. |